Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

Poly(ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and PARP2. Talazoparib, the most potent PARPI inhibitor (PARPI), exhibits remarkable selectivity among the NCI-60 cancer cell lines beyond BRCA inactivation. Our genomic analyses reveal high correlation between respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Murai, Junko, Feng, Ying, Yu, Guoying K., Ru, Yuanbin, Tang, Sai-Wen, Shen, Yuqiao, Pommier, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340226/
https://www.ncbi.nlm.nih.gov/pubmed/27708213
http://dx.doi.org/10.18632/oncotarget.12266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340226/
https://www.ncbi.nlm.nih.gov/pubmed/27708213
http://dx.doi.org/10.18632/oncotarget.12266

Ejemplares similares